Sharon Namasambi

Sharon Namasambi

Auto-generated profile, based on publicly available information

Sharon Namasambi

Uganda Public Health Fellowship Program, Uganda National Institute of Public Health, Kampala, Uganda

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 September 2024 in Open Forum Infectious Diseases
Verified
Journal Article
Open access
PDF file
CACollins Ankunda
Collins Ankunda
CACurthbert Agolor
Curthbert Agolor
YKYvonne Karamagi
Yvonne Karamagi
SNSusan Nakubulwa
Susan Nakubulwa
SNSharon Namasambi
Sharon Namasambi
BMBarbara Mukasa
Barbara Mukasa
Dolutegravir (DTG), a key component of the recommended human immunodeficiency virus (HIV) treatment regimens in Uganda, has been associated with hyperglycemia. We evaluated its influence on hyperglycemia risk to create a hyperglycemia risk stratification tool for patient monitoring. We conducted a prospective cohort study at 3 sites with 628 HIV-positive patients on tenofovir disoproxil fumarate, lamivudine, and dolutegravir (TLD). Participants included both nucleoside reverse transcriptase inhibitor–experienced (exposed) and antiretroviral therapy (ART)–naive (nonexposed) groups. Follow-up occurred every 6 months with random blood sugar (RBS) testing every 3 months. Participants with RBS ≥7 mmol/L were classified as hyperglycemic and underwent glycated hemoglobin (HbA1c) testing, confirming diabetes with a 6.5% cut-off. The study found a hyperglycemia incidence rate of 24.5 (95% confidence interval [CI], 19.3–31.1) cases per 100 person-years (PY) and a diabetes incidence rate of 5.8 cases (95% CI, 3.6–9.3) per 100 PY. Hyperglycemia incidence was slightly lower in nonexposed (20.8 cases per 100 PY) versus exposed groups (25.2 cases per 100 PY). Multivariable analysis indicated a trend toward lower hyperglycemia risk (adjusted hazard ratio [aHR], 0.78 [95% CI, .37–1.66]; P = .52) and substantially lower diabetes incidence (aHR, 0.34 [95% CI, .04–2.82]; P = .32) in the nonexposed group. Significant factors for hyperglycemia included age (P < .001), study site (P < .001), and DTG-based ART duration (P = .02). Our study showed an increased incidence of hyperglycemia with age, study site, and duration of DTG exposure in people with HIV on TLD. We suggest integrated screening and care for hyperglycemia and diabetes in HIV services, especially when initiating DTG regimens.

10 July 2026 in Discover Public Health
Verified
Journal Article
Open access
PDF file
SNSharon Namasambi
Sharon Namasambi
RMRichard Migisha
Richard Migisha
VKVianney John Kigongo
Vianney John Kigongo
MNMaria Nakabuye
Maria Nakabuye
LBLilian Bulage
Lilian Bulage
AAAlex Riolexus Ario
Alex Riolexus Ario
On May 27, 2025 a measles outbreak was confirmed in Kabulasoke Subcounty, Gomba District, Uganda, following a suspected measles-related death. We investiga

19 August 2025 in medRxiv
Verified
Preprint
Open access
PDF file
CACollins Ankunda
Collins Ankunda
SNSharon Namasambi
Sharon Namasambi
CACurthbert Agolor
Curthbert Agolor
SNSusan Nakubulwa
Susan Nakubulwa
YKYvonne Karamagi
Yvonne Karamagi
HNHelen Byomire Ndagije
Helen Byomire Ndagije
Background: Dolutegravir (DTG)–based antiretroviral therapy (ART) is recommended as first⍰line treatment for people living with HIV (PLHIV) in Uganda. However, data on its safety profile in routine care remain limited. This study actively monitored adverse events (AEs) among PLHIV receiving DTG ⍰based regimens, assessing factors associated with their occurrence. Methods: We conducted a prospective cohort study nested within a parent cohort from July 2021 to September 2022 a cross three Ugandan sites (urban, peri ⍰urban, and rural). Adults on DTG/lamivudine/tenofovir (TLD), either transitioning from prior ART regimens or initiated on TLD as first⍰line therapy, were followed for six months. AEs were systematically captured using structured interviews and classified by the Medic al Dictionary for Regulatory Activities (MedDRA) System Organ Class. Univariable and multivariable logistic regression analyses identified predictors of AEs. Results: Among 607 participants, 50 (8.0%) reported adverse events (AEs). Neuropsychiatric disorders were most common (2.5%), followed by cardiovascular (1.8%) and reproductive system disorders (1.5%). Other AEs, including gastrointestinal, eye, and skin disorders, were rare (<1%). In multivariable analysis, participants at site □3 and being single had significantly lower odds of AEs (aOR □0.04, 95%□CI□0.00–0.29, p □=□0.002), (a OR□0.45, 95%□CI□0.22–0.92, p □=□0.028). Prior exposure to Zidovudine-based regimens was associate d with increased odds of AEs (aOR □3.33, 95%□CI□1.43–7.75, p □=□0.005). Conclusion: DTG⍰based ART regimens demonstrated a favourable safety profile, with AEs occurring infrequently and predominantly in neuropsychiatric, cardiovascular, and reproductive categories. Study site, Marital status and prior Zidovudine exposure were associated with AE risk, emphasizing the need for tailored monitoring, strengthened awareness in AE reporting and standardized pharm acovigilance across facilities.

9 October 2026 in SSRN Electronic Journal
Verified
Preprint
Open access
SNSharon Namasambi
Sharon Namasambi
Richard MigishaRichard Migisha
Richard Migisha
CACollins Ankunda
Collins Ankunda
VKVianney John Kigongo
Vianney John Kigongo
PAPauline Achom
Pauline Achom
AAAlex Riolexus Ario
Alex Riolexus Ario
Background: By April 2025, Uganda had reported over 5,000 confirmed Mpox cases and 40 deaths across more than half of the country’s districts placing substantial strain on the healthcare system. However, data on recovery time and factors associated with delayed recovery were limited. We estimated the median time to recovery and identified its predictors among hospitalised patients with Mpox in southwestern Uganda. Methods: We conducted a retrospective cohort study of laboratory-confirmed patients with Mpox admitted in Mbarara Regional Referral Hospital (October 2024–April 2025. Time to recovery was defined from symptom onset to discharge following lesion resolution. Kaplan–Meier methods estimated median recovery time, and Cox regression identified predictors. Results: Among 278 patients (mean age 30 years; 54% male), median recovery time was 16 days (IQR 12–22). Most patients (87%) sought care late. Delayed care seeking was associated with slower recovery (aHR=0.12, 95% CI 0.05–0.28), as was severe disease (aHR=0.63, 95% CI 0.47–0.84). Urban residence was associated with faster recovery (aHR=1.53, 95% CI 1.10–2.13). Conclusion: Recovery was prolonged among patients presenting late and with severe disease. Promoting early care seeking and timely clinical management could reduce hospital burden during Mpox outbreaks.

28 April 2026 in Open Forum Infectious Diseases
Verified
Journal Article
Open access
CACollins Ankunda
Collins Ankunda
SNSharon Namasambi
Sharon Namasambi
CACurthbert Agolor
Curthbert Agolor
SNSusan Nakubulwa
Susan Nakubulwa
YKYvonne Karamagi
Yvonne Karamagi
HNHelen Byomire Ndagije
Helen Byomire Ndagije
Background: Dolutegravir (DTG)-based antiretroviral therapy (ART) is recommended as first-line treatment for people living with HIV-1 (PLHIV) in Uganda. However, data on its safety profile in routine care remain limited. This study actively monitored adverse events (AEs) among PLHIV receiving DTG-based regimens, assessing factors associated with their occurrence. Methods: We conducted a prospective cohort study nested within a parent cohort from July 2021 to September 2022 across 3 Ugandan sites (urban, peri-urban, and rural). Adults on DTG/lamivudine/tenofovir (TLD), either transitioning from prior ART regimens or initiated on TLD as first-line therapy, were followed for 6 months. AEs were systematically captured using structured interviews and classified by the Medical Dictionary for Regulatory Activities System Organ Class. Univariable and multivariable logistic regression analyses identified predictors of AEs. Results: Among 607 participants, 50 (8.2%) reported adverse events (AEs). Neuropsychiatric disorders were most common (2.5%), followed by cardiovascular (1.8%) and reproductive system disorders (1.5%). Other AEs, including gastrointestinal, eye, and skin disorders, were rare (<1%). In multivariable analysis, participants at site 3 and being single had significantly lower odds of AEs (aOR 0.04, 95% CI 0.00–0.29, P = .002), (aOR 0.45, 95% CI 0.22–0.92, P = .028). Prior exposure to Zidovudine-based regimens was associated with increased odds of AEs (aOR 3.33, 95% CI 1.43–7.75, P = .005). Conclusions: DTG-based ART regimens demonstrated a favorable safety profile, with AEs occurring infrequently and predominantly in neuropsychiatric, cardiovascular, and reproductive categories. Study site, Marital status and prior Zidovudine exposure were associated with AE risk, emphasizing the need for tailored monitoring, strengthened awareness in AE reporting and standardized pharmacovigilance across facilities.

10 August 2026 in medRxiv
Verified
Preprint
Open access
PDF file
SNSharon Namasambi
Sharon Namasambi
RMRichard Migisha
Richard Migisha
CACollins Ankunda
Collins Ankunda
YNYasiini Nuwamanya
Yasiini Nuwamanya
PAPauline Achom
Pauline Achom
AAAlex Riolexus Ario
Alex Riolexus Ario
Background: Measles outbreaks in Uganda persist despite the availability of an effective vaccine, suggesting persistent immunity gaps and health system weaknesses. We conducted a multi-district outbreak causality analysis (OCA) to identify programmatic and health-system contributors to measles outbreaks and inform measles elimination programming. Methods: We conducted a cross-sectional mixed-methods OCA across 12 affected districts in Uganda (2025–2026), guided by the World Health Organization framework. We reviewed measles case investigation reports and triangulated findings with qualitative interviews with district health teams, health workers, surveillance and immunisation staff, community leaders, Village Health Teams, and caregivers. We deductively analysed data to identify causal pathways and contributing factors. Findings were organized into four prespecified analytical themes: immunization service delivery, caregiver access and demand, surveillance and case detection, and outbreak preparedness and response. Results: The 12 districts reported 1,302 cases, including 80 laboratory-confirmed cases and 10 suspected deaths (case-fatality rate: 0.77%); 46.5% (n=606) occurred among children aged 18– 59 months. Most cases (65.3%) occurred in unvaccinated children, versus 1.0% in children with both measles-rubella (MR) doses. Across districts, incomplete MR2 implementation, irregular outreach, inconsistent fixed-site vaccination, weak follow-up of children who missed vaccination, and transport and distance barriers contributed to persistent immunity gaps. Low clinical suspicion, limited engagement of Village Health Teams, laboratory and surveillance-information bottlenecks, absence of pre-positioned response plans, delayed response activation, and inadequate isolation capacity further limited early detection and control. Conclusion: Measles outbreaks were driven primarily by missed vaccination, especially incomplete delivery of the two-dose MR schedule, compounded by access barriers, delayed case detection, and limited outbreak preparedness. Strengthening routine MR1 and MR2 delivery, targeted catch-up vaccination, community-linked surveillance, and pre-positioned district response plans with clear activation triggers will be critical to closing immunity gaps and accelerating measles elimination in Uganda.